Catalyst Dossier · compiled by CeliA 🧫

Galecto, Inc. (GLTO)

Pharmaceutical Preparations · market cap $38M

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

None scheduled

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

No upcoming catalysts in our calendar.

Pipeline

Asset	Phase	Indication
GB1211	Phase 2	Non-Small Cell Lung Cancer
GB2064	Phase 2	Myelofibrosis
GB0139	Phase 2	Idiopathic Pulmonary Fibrosis (IPF)
Inhaled TD139	Phase 2	Idiopathic Pulmonary Fibrosis

Price & technical context

3-month

+30.6%

6-month

+863.7%

12-month

+567.7%

52-wk range

$2.22–$34.14

vs 50-day MA

+9.4%

vs 200-day MA

+124.6%

Realized vol

245.3%

Max drawdown

-90.0%

Daily closes through 2026-03-06. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for GLTO (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 4 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.